Steven R Goldsmith Selected Research

Vasopressin Receptors (Arginine Vasopressin Receptor)

2/2021	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.
7/2019	Arginine vasopressin antagonism in heart failure: Current status and possible new directions.
1/2018	Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients withchronic heart failure during submaximal exercise.
1/2018	Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?
5/2016	A new approach to treatment of acute heart failure.
3/2014	Vasopressin receptor antagonists: from pivotal trials to current practice.
10/2008	Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
6/2006	Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure.
5/2006	Treating hyponatremia in heart failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven R Goldsmith Research Topics

Disease

35	Heart Failure 02/2021 - 09/2002
9	Hyponatremia 01/2021 - 05/2005
7	Body Weight (Weight, Body) 02/2021 - 10/2008
6	Dyspnea (Shortness of Breath) 01/2021 - 07/2015
2	Hypertrophy 01/2021 - 09/2002
2	Disease Progression 07/2019 - 06/2006
2	Edema (Dropsy) 07/2015 - 06/2009
2	Cardio-Renal Syndrome 02/2015 - 03/2010
2	Hypertension (High Blood Pressure) 03/2013 - 05/2010
2	Left Ventricular Dysfunction 07/2004 - 09/2002
1	Alkalosis 01/2018
1	Cardiac Arrhythmias (Arrythmia) 01/2017
1	Heart Arrest (Cardiac Arrest) 01/2017
1	Exanthema (Rash) 05/2015
1	Weight Loss (Weight Reduction) 12/2012
1	Obesity 11/2012
1	Ventricular Remodeling 06/2006

Drug/Important Bio-Agent (IBA)

11	Arginine Vasopressin (Argipressin)IBA 01/2021 - 09/2002
10	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 02/2021 - 05/2005
9	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 02/2021 - 05/2006
9	Vasopressins (Vasopressin)IBA 01/2021 - 11/2005
9	DiureticsIBA 12/2017 - 03/2011
8	Tolvaptan FDA Link 10/2017 - 05/2005
7	Antidiuretic Hormone Receptor AntagonistsIBA 02/2021 - 06/2006
4	conivaptan (Vaprisol)FDA Link 01/2018 - 05/2005
4	SodiumIBA 12/2017 - 05/2005
4	Furosemide (Lasix)FDA LinkGeneric 10/2017 - 05/2005
4	ElectrolytesIBA 10/2013 - 05/2005
2	CreatinineIBA 02/2021 - 12/2012
2	Urea (Carbamide)FDA LinkGeneric 02/2021 - 05/2005
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 03/2013 - 11/2007
1	NitrogenIBA 02/2021
1	Angiotensin IIIBA 01/2021
1	Bicarbonates (Hydrogen Carbonate)IBA 01/2018
1	Allopurinol (Remid)FDA LinkGeneric 05/2015
1	Xanthine OxidaseIBA 05/2015
1	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2013
1	Dopamine (Intropin)FDA LinkGeneric 12/2013
1	Adrenergic Agents (Adrenergic Drugs)IBA 11/2005
1	lixivaptanIBA 05/2005
1	Lithium Carbonate (Eskalith)FDA LinkGeneric 05/2005
1	Demeclocycline (Declomycin)FDA LinkGeneric 05/2005
1	Hypertonic Saline SolutionIBA 05/2005

Therapy/Procedure

19	Therapeutics 02/2021 - 09/2002
1	Patient Readmission 12/2017
1	Induced Hypothermia 01/2017
1	Drug Therapy (Chemotherapy) 05/2010